[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":88,"collaborators":11,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":11,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"SCG Cell Therapy Pte. Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SCG101","EXPERIMENTAL",null,[13],"Biological: SCG101",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"SCG Cell Therapy","CONTACT","021-50339500","clinicaltrials@scgcell.com",[26,39,48,57,66,75,79],{"facility":27,"status":28,"city":27,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"Beijing","RECRUITING","Beijing Municipality","100020","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},{"facility":40,"status":28,"city":40,"state":41,"zip":42,"country":31,"countryCode":32,"cosmosGeoPoint":43,"geoPoint":47,"contacts":11},"Guangzhou","Guangdong","510000",{"type":34,"coordinates":44},[45,46],113.25,23.11667,{"lat":46,"lon":45},{"facility":49,"status":28,"city":49,"state":50,"zip":51,"country":31,"countryCode":32,"cosmosGeoPoint":52,"geoPoint":56,"contacts":11},"Zhengzhou","Henan","450003",{"type":34,"coordinates":53},[54,55],113.64861,34.75778,{"lat":55,"lon":54},{"facility":58,"status":28,"city":58,"state":59,"zip":60,"country":31,"countryCode":32,"cosmosGeoPoint":61,"geoPoint":65,"contacts":11},"Changchun","Jilin","130000",{"type":34,"coordinates":62},[63,64],125.32278,43.88,{"lat":64,"lon":63},{"facility":67,"status":28,"city":67,"state":68,"zip":69,"country":31,"countryCode":32,"cosmosGeoPoint":70,"geoPoint":74,"contacts":11},"Shenyang","Liaoning","110000",{"type":34,"coordinates":71},[72,73],123.43278,41.79222,{"lat":73,"lon":72},{"facility":76,"status":28,"city":76,"state":77,"zip":78,"country":31,"countryCode":32,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Ji'nan","Shandong","250000",{"facility":80,"status":28,"city":80,"state":81,"zip":82,"country":31,"countryCode":32,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"Shanghai","Shanghai Municipality","200000",{"type":34,"coordinates":84},[85,86],121.45806,31.22222,{"lat":86,"lon":85},{"type":89,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100563502","phase-1-a-study-of-scg101-tcr-t-cell-therpay-in-the-treatment-of-subjects-with-hepatitis-b-virus-related-100563502",false,"NCT06617000","A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","A Phase 1, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)\n* Subjects with HCC who have received standard systemic therapies\n* HLA-A \\*02\n* BCLC stage B or C\n* Child-pugh score ≤ 7 ol\n* Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be ≤ 1 × 1000 IU\u002Fml\n* Have at least one measurable leasion at baseline as per mRECIST and iRECIST\n* Life expectancy of 3 months or greater\n* The organ function is in good condition.\n\nExclusion Criteria:\n\n* Subjects with history of another primary cancer within 5 years\n* Central nervous system metastasis and clinically significant central nervous system disease\n* Previous or current coexistence of hepatic encephalopathy\n* Currently present with symptomatic third space fluid accumulation\n* Hypertension that is poorly controlled, as determined by researchers (i.e., arterial hypertension that remains uncontrolled despite standard treatment)\n* Known history of neurological or mental disorder, including epilepsy or dementia\n* Suffering from active autoimmune diseases, or other significant ongoing immune rejection based on pathology and clinical diagnosis\n* Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy\n* Positive for HCV - RNA test or positive for HAV IgM antibody or positive for HDV IgM antibody; or there is current evidence indicating the presence of HEV infection\n* Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)\n* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation","ALL","18 Years","70 Years",{"count":101,"type":102},38,"ESTIMATED","INTERVENTIONAL",[105],"PHASE1","This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.",[108,109,110],"HCC","Hepatitis B Virus Related Hepatocellular Carcinoma","Hepatocellular Carcinoma","2024-09-25",{"date":113,"type":114},"2024-09-27","ACTUAL",{"date":116,"type":114},"2022-10-25",{"date":118,"type":102},"2025-12-31",{"name":5,"class":6},7]